The Design and Initial Survival Analysis Outcomes from the STAMPEDE Trial - an eSeries supported by SIU’s corporate sponsor, Sanofi Oncology
SIU Academy®. James N. 12/15/15; 108697
Topic: Research
CLICK HERE TO LOGIN
REGULAR CONTENT
REGULAR CONTENT
Login now to access Regular content available to all registered users.
To have an exclusive access to the entire content available on SIU Academy, become an SIU Member here.
To have an exclusive access to the entire content available on SIU Academy, become an SIU Member here.
Learning Objectives
Discussion Forum (0)
Rate & Comment (0)
After viewing this presentation the participant will be able to:
- Explain the changing prognosis of men starting long-term ADT
- Define the role of radiotherapy in M0 disease
- Discuss the role of chemotherapy in hormone-naïve prostate cancer
- Understand the evolving data on use of zoledronic acid in prostate cancer
- Explain the changing prognosis of men starting long-term ADT
- Define the role of radiotherapy in M0 disease
- Discuss the role of chemotherapy in hormone-naïve prostate cancer
- Understand the evolving data on use of zoledronic acid in prostate cancer
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}
